Hyperfine, Inc. Class A HYPR
NASDAQ · United States · Health Technology
$0.8938+0.02 (+2.54%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
GUILFORD, Conn., September 28, 2026--Hyperfine appoints Roots Pharmaceutical as exclusive Swoop system distributor in the United Arab Emirates and Kuwait.
MENLO PARK, Calif., September 16, 2026--MedtechWOMEN today announced that Maria Sainz, President and CEO of Hyperfine, Inc., has been named the recipient of its 2026 Ferolyn Powell Leadership Award, and that Beverly Tang, co-founder and CEO of Starlight Cardiovascular, has received MedtechWOMEN’s first-ever Rising Star Award. Both leaders were recognized at the annual MedtechVISION Annual Conference at the Rosewood Sand Hill in Menlo Park, Calif.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
GUILFORD, Conn., September 15, 2026--Completion of enrollment in study to support anticipated indication expansion for use of the Swoop® system with contrast agents.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.